RCSA
MRNA icon

REYL & Cie S.A.’s Moderna MRNA Stock Holding History

REYL & Cie S.A.’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Buy
+452
New +$23.4K 0.03% 131

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

REYL & Cie S.A.'s MRNA Position: Q2 2026 in Review

REYL & Cie S.A. opened a new position in Moderna (MRNA) in Q2 2026: 452 shares worth $23K. The stake represents 0.03% of the portfolio and ranks #131 among its holdings.

784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • REYL & Cie S.A. held 452 shares of Moderna worth $23K as of Q2 2026.
  • Moderna was a new REYL & Cie S.A. position in Q2 2026.
  • Moderna made up 0.03% of REYL & Cie S.A.'s portfolio in Q2 2026, its #131 holding.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on REYL & Cie S.A.'s 13F filing for Q2 2026, filed 2 Oct 2026.